R&D | April 13, 2026
Merck India, MAHE launch catalyst program to build future R&D talent pipeline
MoU aims to strengthen academia-industry collaboration in healthcare research and innovation
MoU aims to strengthen academia-industry collaboration in healthcare research and innovation
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network
Its a major breakthrough for women’s ovarian cancer care in Europe
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
SPARK has extended its influence to an additional 9.47 million students worldwide
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Subscribe To Our Newsletter & Stay Updated
